PR84225

PARIS, June 4, 2020 /PRNewswire=KYODO JBN/ --

Servier, an independent international pharmaceutical company, today announced

that it has completed the acquisition of Symphogen A/S.

Symphogen will now function as Servier’s antibody center of excellence across

multiple different therapeutic areas, including oncology. Symphogen, now a

Servier subsidiary, will keep its operational autonomy and continue to rely on

its experienced employees while maintaining its headquarters in Ballerup,

Denmark.

As part of the acquisition, Christophe Thurieau, Executive Director of Servier

Research Institute, has been appointed Chief Executive Officer of Symphogen and

Karin Garre, former Chief Operating Officer of Symphogen, has been appointed

General Manager of Symphogen. Martin Olin, former Chief Executive Officer of

Symphogen, will act as an external consultant to support this transition.  

Claude Bertrand, Executive Vice-President Research & Development at Servier,

said: "The completion of this acquisition enables Servier to boost its antibody

capabilities in oncology and its other therapeutic areas. The efficient

antibody discovery and research platform of Symphogen will strengthen our R&D

capabilities and pipeline in line with our aim of making life-saving treatments

available to more patients across the world."

Christophe Thurieau, Executive Director of Servier Research Institute and Chief

Executive Officer of Symphogen, added: "In line with the values of Symphogen,

we also strongly believe that innovation and collaboration are key to develop

treatments for the benefit of patients. We are very pleased to welcome

Symphogen as part of the Servier Group and look forward to further

collaborating with the team on developing breakthrough antibody therapies for

patients."

Karin Garre, General Manager of Symphogen, concluded: "The completion of this

transaction marks a very exciting journey for Symphogen and Servier. Anchored

in a pre-existing strategic collaboration, this acquisition supports the R&D

strategy of Servier within antibodies thanks to the capabilities of Symphogen.

As the two organizations share key values, I believe this unification is

positioned for a great outcome going forward."  

PDF: https://mma.prnewswire.com/media/1175338/Servier_PDF_EN.pdf  

Logo: https://mma.prnewswire.com/media/1175327/Servier_Logo.jpg  

Contact:

Sonia Marques, presse@servier.com, Tel. +33(0)1-55-72-40-21 /

+33(0)7-84-28-76-13.

Jean-Clément Vergeau, presse@servier.com, Tel. +33(0)1-55-72-46-16 /

+33(0)6-79-56-75-96.

Source: Servier